Trial Search Results
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: National Institutes of Health (NIH)
Stanford Investigator(s):
Intervention(s):
- Procedure: nonmyeloablative allogeneic hematopoietic cell transplant
Phase:
N/A
Eligibility
Inclusion Criteria:- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- HLA matched donor available Exclusion Criteria:- organ dysfunction
- HIV positive
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822